Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Blood Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Granulocyte-Colony Stimulating Factor (G-CSF) Drugs key companies include Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio and Intas, etc. Amgen, Kyowa Kirin, Chugai Pharmaceutical are top 3 players and held % share in total in 2022.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs can be divided into Filgrastim, Pefigrastim and Lipefigrastim,, etc. Filgrastim is the mainstream product in the market, accounting for % share globally in 2022.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is widely used in various fields, such as Oncology, Blood Disease and Other,, etc. Oncology provides greatest supports to the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry development. In 2022, global % share of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amgen
Kyowa Kirin
Chugai Pharmaceutical
Novartis
Teva
Pfizer
Merck
Dong-A Socio
Intas
GenSci
Dr. Reddy
Amoytop
North China Pharmaceutical
SL Pharm
Hayao Group
Segment by Type
Filgrastim
Pefigrastim
Lipefigrastim
Oncology
Blood Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Granulocyte-Colony Stimulating Factor (G-CSF) Drugs introduction, etc. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Blood Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Granulocyte-Colony Stimulating Factor (G-CSF) Drugs key companies include Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio and Intas, etc. Amgen, Kyowa Kirin, Chugai Pharmaceutical are top 3 players and held % share in total in 2022.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs can be divided into Filgrastim, Pefigrastim and Lipefigrastim,, etc. Filgrastim is the mainstream product in the market, accounting for % share globally in 2022.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is widely used in various fields, such as Oncology, Blood Disease and Other,, etc. Oncology provides greatest supports to the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry development. In 2022, global % share of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen
Kyowa Kirin
Chugai Pharmaceutical
Novartis
Teva
Pfizer
Merck
Dong-A Socio
Intas
GenSci
Dr. Reddy
Amoytop
North China Pharmaceutical
SL Pharm
Hayao Group
Segment by Type
Filgrastim
Pefigrastim
Lipefigrastim
Segment by Application
Oncology
Blood Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Granulocyte-Colony Stimulating Factor (G-CSF) Drugs introduction, etc. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices